TD Cowen Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $60.00

Travere Therapeutics (NASDAQ:TVTX) had its price target upped by equities research analysts at TD Cowen from $45.00 to $60.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target points to a potential upside of 35.92% from the stock’s previous close.

Several other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. Guggenheim increased their price objective on shares of Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. Wedbush increased their price objective on shares of Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Tuesday. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Piper Sandler upgraded shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price on the stock in a report on Tuesday, April 14th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.58.

Travere Therapeutics Trading Down 1.7%

NASDAQ TVTX traded down $0.77 during trading hours on Tuesday, hitting $44.15. The company’s stock had a trading volume of 2,219,472 shares, compared to its average volume of 2,151,058. The stock has a fifty day moving average of $32.02 and a 200 day moving average of $32.59. Travere Therapeutics has a twelve month low of $13.88 and a twelve month high of $48.61. The firm has a market capitalization of $4.08 billion, a P/E ratio of -147.15 and a beta of 1.13. The company has a quick ratio of 2.70, a current ratio of 2.74 and a debt-to-equity ratio of 2.71.

Insiders Place Their Bets

In other Travere Therapeutics news, Director Roy D. Baynes sold 9,750 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $44.22, for a total value of $431,145.00. Following the transaction, the director directly owned 37,500 shares of the company’s stock, valued at $1,658,250. This trade represents a 20.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth E. Reed sold 6,785 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $41.83, for a total transaction of $283,816.55. Following the completion of the transaction, the insider directly owned 105,211 shares in the company, valued at approximately $4,400,976.13. This represents a 6.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 317,370 shares of company stock worth $12,100,486. 4.44% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TVTX. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the 2nd quarter worth approximately $33,000. Fifth Third Bancorp acquired a new position in shares of Travere Therapeutics during the 1st quarter valued at $35,000. First Horizon Corp acquired a new position in shares of Travere Therapeutics during the 3rd quarter valued at $36,000. State of Wyoming acquired a new position in shares of Travere Therapeutics during the 4th quarter valued at $37,000. Finally, Torren Management LLC bought a new stake in Travere Therapeutics during the 4th quarter valued at $38,000.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Company update: Travere highlighted a landmark approval of FILSPARI in FSGS, strong demand (including continued momentum in IgAN), and the restart/first new patient dosed in the Phase 3 HARMONY study for pegtibatinase — positive commercial and pipeline catalysts that support longer-term revenue growth. Travere Therapeutics Reports First Quarter 2026 Financial Results
• Positive Sentiment: Analyst support: several firms have raised targets or maintain buy/outperform views recently, providing third‑party validation for the commercial outlook and helping underpin the stock despite short-term noise. MarketBeat TVTX coverage
• Neutral Sentiment: Earnings call details: management commentary and the full Q1 transcript are available for investors to evaluate guidance, channel trends, and commercial execution described on the call. Review for nuance on demand trends and margin cadence. Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Mixed quarter metrics: coverage notes the quarter showed strong year‑over‑year revenue growth but divergence vs. consensus on key line items — read the “compared to estimates” pieces for detail on which metrics beat or missed. Compared to Estimates, Travere (TVTX) Q1 Earnings
• Negative Sentiment: Revenue miss / mixed headline results: some outlets report the quarter missed revenue estimates and show variability in EPS comparisons across data providers — that topline shortfall is a near‑term catalyst for selling pressure. Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Insider selling: Director Roy Baynes sold 9,750 shares under a pre‑arranged Rule 10b5‑1 plan; while planned sales reduce alarm compared with opportunistic selling, the disclosure can still weigh on sentiment. Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Director Sells 9,750 Shares of Stock

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.